JNK inhibitor IX restrains pancreatic cancer through p53 and p21

Novel treatment options for pancreatic cancer are desperately needed. De-regulated kinases can be regularly detected in pancreatic cancer. Multiple pathway inhibitors were developed to exploit these features, among them selective inhibitors of the c-Jun N-terminal kinase isoforms 1 and 2 (JNK1 and 2...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Jingwei, Yang, Xing, Kang, Qi, Lu, Jian, Denzinger, Maximilian, Kornmann, Marko, Traub, Benno
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9768178/
https://www.ncbi.nlm.nih.gov/pubmed/36568248
http://dx.doi.org/10.3389/fonc.2022.1006131

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9768178/
https://www.ncbi.nlm.nih.gov/pubmed/36568248
http://dx.doi.org/10.3389/fonc.2022.1006131

Ejemplares similares